

# IQoro is an innovative treatment for reflux-based diseases as an alternative to long-term PPI medication or surgery

IQoro is a new and innovative treatment for Hiatal hernia and dysphagia that is listed on the Drug Tariff from May 1st, 2022.



IQoro is a neuromuscular treatment that stimulates normal sensory and motor nerve activity to strengthen and coordinate weakened musculature, including that in the diaphragm that allows acid reflux.

IQoro is a simple handheld device that a patient usually self-treats with in three daily training sessions of 30 seconds each.

# Treating the symptoms of Hiatal hernia

Patients with Dyspepsia, GORD, Silent reflux, LPR and other acid reflux-based conditions can be advised to make lifestyle changes, or may be prescribed medication – often PPI drugs - or ultimately referred for surgery.

IQoro is a simple neuromuscular treatment that addresses the most common cause of the following symptoms: a Hiatal hernia, whether or not this condition has been confirmed by internal examination.


- Acidic reflux
- Heartburn
- Hoarseness
- Feeling of a lump in the throat
- Feeling of a blockage in the chest when eating
- Pain under the sternum
- Persistent dry or phlegmy cough
- Swallowing difficulties

## How IQoro works

When first inserted, and during the training sequence, IQoro stimulates the sensory nerves to send intense bursts of stimuli to the brain stem via the upward transmitting “afferent” nerves.

This stimulation provokes a sensory motor nerve reflex arc that causes the downward transmitting “efferent” nerves to send motor signals to the 148 muscles in the swallowing chain, and to other muscles controlled by the autonomic system. In this way the smooth musculature involved in holding the stomach in its correct position beneath the diaphragm can be activated, exercised and strengthened.

Afferent signal  
- up to the brain  
Sensation/feeling  
Pressure  
Touch  
Taste  
Temperatue



Efferent signal  
- from the brain  
to the muscles

# Scientific evidence

IQoro efficacy is supported by 15 peer-reviewed and internationally published scientific studies. Three of these studies were referenced by NICE in a Medtech Innovation Briefing (MIB 176),

"all patients continued with their PPI medication as advised. As symptoms reduced, patients ceased to medicate. Use or cessation of PPIs was under the control of the patients' doctors. At end-of-training in the 3 studies quoted 93%, 58% and 61% ceased all PPI medication, the remainder mostly reduced dose and intake frequency".

# Contraindications

In our clinical experience, there are three contra-indications that preclude the use of IQoro:

- Trigeminal neuralgia
- Paraesophageal hernia
- Achalasia Cardiae

And these two conditions require extra thought and care:

- Tinnitus
- Peripheral facial palsy

See our website for more details: [www.iqoro.com/what-is-iqoro/when-is-iqoro-suitable-or-not-suitable-for-use/](http://www.iqoro.com/what-is-iqoro/when-is-iqoro-suitable-or-not-suitable-for-use/)

# Prescribing details

IQoro is listed in the Drug Tariff Part IX from May 1st, 2022. It can be found under 'Appliances' in the category 'Neuromuscular Treatment Devices'.

The two versions of IQoro listed there are:

- Adult size 214-001T
- Child size 214-002T (normally up to 12 years old)